Riskpilot← Back to searchSign inGet full accessSanofi A/S
A/SActiveCVR 19064301Lyngbyvej 2Wholesale of pharmaceutical and medical goods · NACE 4646Est. 199683 employees
Revenue 2024
DKK 452,6M
-14% vs 2023
EBITDA margin
2.2%
+35% vs 2023
Equity ratio
27.9%
Financial strength
Net profit 2024
DKK 6,2M
+68% vs 2023
| Revenue | DKK 452,6M | -14% |
| EBITDA | DKK 10M | +35% |
| Net profit | DKK 6,2M | +68% |
| Total assets | DKK 192M | +16% |
| Equity | DKK 53,6M | +13% |
| Employees | 83 | — |
Legal name
Sanofi A/S
CVR number
19064301
Legal form
Aktieselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
15. januar 1996
Share capital
DKK 7.000.000
Employees
83 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den samlede bestyrelse, af et medlem af bestyrelsen eller af en direktør.
Company purpose
Selskabets formål er at drive handel og produktion af farmaceutiske produkter og alle aktiviteter, der relaterer sig til research, udvikling, produktion, udnyttelse og marketing af bio-farmaceutiske og farmaceutiske produkter, inklusive vacciner, serummer, immummodulatoer og produkter afledt fra bio-teknologi og højteknologi beregnet til humanmedicinske lægemidler.
Address
Lyngbyvej 2
Phone
+4545167000
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 255.285 | 304.314 | 393.188 | 435.538 | 421.220 | 433.862 | 485.721 | 563.450 | 591.149 | 530.879 | 527.584 | 452.617 |
| Staff expenses | -63.823 | -70.254 | -77.029 | -78.970 | -96.059 | -100.669 | -103.011 | -115.558 | -97.327 | -93.946 | -95.112 | -97.075 |
| EBITDA | 8.926 | 21.668 | 533 | 12.774 | 17.266 | -1.997 | 11.930 | 88.054 | 38.348 | 21.050 | 7.425 | 10.020 |
| Depreciation & amort. | -514 | -560 | -525 | -437 | -382 | -111 | -964 | -1.154 | -3.911 | -440 | -440 | -455 |
| EBIT | 8.412 | 21.108 | 8 | 12.337 | 16.884 | -2.108 | 10.966 | 86.900 | 34.437 | 20.610 | 6.985 | 9.565 |
| Net financials | -21.326 | 11.539 | -444 | -819 | -296 | -317 | -278 | 578 | -2.462 | -1.344 | -1.308 | -669 |
| Profit before tax | -12.913 | 32.647 | 35.998 | 11.518 | 16.588 | -2.426 | 10.688 | 87.478 | 31.975 | 19.266 | 5.677 | 8.896 |
| Tax | 3.254 | 7.634 | 9.875 | 3.829 | 4.958 | 631 | 3.465 | 20.263 | 9.993 | 3.347 | 1.980 | 2.679 |
| Net profit | -16.168 | 25.013 | 26.123 | 7.689 | 11.630 | -3.056 | 7.223 | 67.215 | 21.982 | 15.919 | 3.697 | 6.217 |
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 162.284 | 160.018 | 192.046 | 191.286 | 160.424 | 176.845 | 164.663 | 225.760 | 223.188 | 179.873 | 166.242 | 192.036 |
| Equity | 78.721 | 68.734 | 59.857 | 32.546 | 19.176 | 16.120 | 23.343 | 77.175 | 69.317 | 43.706 | 47.403 | 53.620 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 3.476 | 10.946 | 0 | 0 | 0 | 0 |
| Short-term debt | 83.483 | 91.283 | 132.189 | 158.740 | 141.248 | 160.725 | 137.844 | 137.640 | 153.871 | 136.167 | 118.839 | 138.416 |
| Total debt | 83.483 | 91.283 | 132.189 | 158.740 | 141.248 | 160.725 | 141.320 | 148.585 | 153.871 | 136.167 | 118.839 | 138.416 |
EBITDA margin
2.2%
This company
15.8%
Market median
-86% vs market
20132024
Equity ratio
27.9%
This company
38.2%
Market median
-27% vs market
20132024
Return on equity
11.6%
This company
18.4%
Market median
+37% vs market
20132024
Net profit margin
1.4%
This company
8.1%
Market median
-83% vs market
20132024
Asset turnover
2.36×
This company
1.12×
Market median
+111% vs market
20132024
Debt / equity
2.58×
This company
0.62×
Market median
-316% vs market
20132024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
RV Chief Executive Officer | Chief Executive Officer | 2018 | — | — |
OA Management | Management | 2025 | — | — |
US Management | Management | 1996 | — | — |
ET | Audit | 1996 | — | — |
DA Management | Management | 2024 | — | — |
CS Chief Executive Officer | Chief Executive Officer | 2016 | — | — |
FS Management | Management | 2024 | — | — |
LR Chief Executive Officer | Chief Executive Officer | 2008 | — | — |
PA Management | Management | 1999 | — | — |
JV Chief Executive Officer | Chief Executive Officer | 2004 | — | — |
PE Management | Management | 1996 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 1996 | — | — | |
| Chairman | 2006 | — | — | |
| Chairman | 2007 | — | — | |
| Board of Directors | 2011 | — | — | |
| Chairman | 2024 | — | — | |
| Chairman | 2004 | — | — | |
| Chairman | 1996 | — | — | |
| Chairman | 2008 | — | — | |
| Board of Directors | 2019 | — | — | |
| Chairman | 2009 | — | — | |
| Board of Directors | 2000 | — | — | |
| Chairman | 2012 | — | — | |
| Board of Directors | 2000 | — | — | |
| Board of Directors | 2025 | — | — | |
| Chairman | 2001 | — | — | |
| Chairman | 2016 | — | — | |
| Board of Directors | 1996 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2013 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Sanofi A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Rasmus Villemoes | Chief Executive Officer | 0 companies |
| Odd Arne Gabriel Johannessen | Management | 0 companies |
| Ursula Sara Barbro Tengelin | Management | 0 companies |
| Erik Tronborg Andersen | Audit | 0 companies |
| Daniel Andreas Sandgren | Management | 0 companies |
| Charlotte Søby Vestergaard | Chief Executive Officer | 0 companies |
| Fiona Sylvie Simone de Bouvere | Management | 0 companies |
| Lasse Richter Petersen | Chief Executive Officer | 0 companies |
| Per Aage Gregor Christensen | Management | 0 companies |
| Joannes Victor Maria Hendrickx | Chief Executive Officer | 0 companies |
| Per Emil Hasselbalch Stakemann | Management | 0 companies |
| Ulf Svejgaard Poulsen | Chairman | 0 companies |
| Jean-Marie Argeles | Chairman | 0 companies |
| Colette Mutschler | Chairman | 0 companies |
| Stéphane Marie Jean Amédée Malphettes | Board of Directors | 0 companies |
| Birgitte Fyhn | Chairman | 0 companies |
| Peter Antoon Hugo Guenter | Chairman | 0 companies |
| Philip Oswald Burchard | Chairman | 0 companies |
| Karen Lykke Sørensen | Chairman | 0 companies |
| Peter Wester Oldenziel | Board of Directors | 0 companies |
| Jean Laurent Dousset | Chairman | 0 companies |
| Flemming Lauritzen | Board of Directors | 0 companies |
| Minna Satu Marketta Kallio | Chairman | 0 companies |
| Roger Hemingway | Board of Directors | 0 companies |
| Hao Zheng | Board of Directors | 0 companies |
| Seppo Antero Silander | Chairman | 0 companies |
| Kirstin Jagd | Chairman | 0 companies |
| Hans Christian Galst | Board of Directors | 0 companies |